Immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugate vaccines in children with conditions associated with impaired antibody responses to type b polysaccharide vaccine.
Weinberg
G A
GA
Edward Mallinckrodt Department of Pediatrics, Washington University School of Medicine, St Louis, Missouri.
Granoff
D M
DM
D000293:Adolescent; D000755:Anemia, Sickle Cell / Q000276:immunology; D000907:Antibodies, Bacterial / Q000096:biosynthesis*; D001428:Bacterial Vaccines; D044383:Black People; D002648:Child; D002675:Child, Preschool; D004168:Diphtheria Toxoid; D006192:Haemophilus Infections / Q000208:ethnology / Q000276:immunology / Q000517:prevention & control; D018073:Haemophilus Vaccines; D006193:Haemophilus influenzae / Q000276:immunology*; D006801:Humans; D017099:IgG Deficiency; D007074:Immunoglobulin G / Q000032:analysis; D007198:Indians, North American; D007223:Infant; D009369:Neoplasms / Q000276:immunology; D014481:United States; D001741:Black or African American
D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D004168:Diphtheria Toxoid; D018073:Haemophilus Vaccines; C052180:Haemophilus influenzae type b-polysaccharide vaccine-diphtheria toxoid conjugate; D007074:Immunoglobulin G